
sourcing the best research evidence in ophthalmology
Low-Concentration Atropine for Myopia Progression (LAMP)
Main finding: At 1 and 2 years, 0.05% atropine was the most effective in controlling spherical equivalent progression and axial length elongation in myopia.
Study characteristics:
- Names: “Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-
- Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control”,
- “Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 2 Report”
- Purpose: To evaluate the efficacy and safety of 0.05%, 0.025%, and 0.01% atropine eye drops for myopia control
- Type: Randomised controlled Trial
- Condition: Myopia
- Year results published: 2019, 2020
Participants: Age 4-12 years old
-myopic refraction at least 1.0D OU
-Astigmatism < 2.5D
-Documented myopic progression of at least 0.5D in the past 1 year
- n=438 patients (1st year), 383 patients (2nd year)
Intervention:
Group 1: Atropine 0.05% once daily
Group 2: Atropine 0.0025% once daily
Group 3: Atropine 0.01% once daily
Group 4: Placebo once daily
In 2nd year, placebo group was placed on Atropine 0.05% once daily
In the placebo group, myopia progression was reduced significantly after switching to 0.05% atropine.
Visual acuity and vision-related quality of life were unaffected, while accommodation loss and pupil size change in all concentrations were well tolerated.
Outcome measure | Time period | Atropine 0.05% | Atropine 0.025% | Atropine 0.01% | Placebo (1st year only) |
---|---|---|---|---|---|
Spherical equivalent change (dioptres) | 1 year | -0.27 | -0.46 | -0.59 | -0.81 |
2 year | -0.55 | -0.85 | -1.12 | ||
Axial length change (mm) | 1 year | 0.20 | 0.29 | 0.36 | 0.41 |
2 year | 0.39 | 0.50 | 0.59 |
Source Archive